LUNG vs. NPCE, TCMD, CERS, BVS, ANIK, SKIN, PLSE, NVRO, OSUR, and GUTS
Should you be buying Pulmonx stock or one of its competitors? The main competitors of Pulmonx include NeuroPace (NPCE), Tactile Systems Technology (TCMD), Cerus (CERS), Bioventus (BVS), Anika Therapeutics (ANIK), Beauty Health (SKIN), Pulse Biosciences (PLSE), Nevro (NVRO), OraSure Technologies (OSUR), and Fractyl Health (GUTS). These companies are all part of the "surgical & medical instruments" industry.
Pulmonx (NASDAQ:LUNG) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
Pulmonx currently has a consensus target price of $16.33, suggesting a potential upside of 87.31%. NeuroPace has a consensus target price of $15.67, suggesting a potential upside of 81.96%. Given Pulmonx's higher probable upside, equities analysts clearly believe Pulmonx is more favorable than NeuroPace.
Pulmonx received 6 more outperform votes than NeuroPace when rated by MarketBeat users. However, 55.81% of users gave NeuroPace an outperform vote while only 43.48% of users gave Pulmonx an outperform vote.
In the previous week, NeuroPace had 16 more articles in the media than Pulmonx. MarketBeat recorded 21 mentions for NeuroPace and 5 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.04 beat NeuroPace's score of 0.52 indicating that Pulmonx is being referred to more favorably in the media.
Pulmonx has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500.
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 5.7% of Pulmonx shares are held by insiders. Comparatively, 22.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NeuroPace has a net margin of -45.61% compared to Pulmonx's net margin of -80.46%. Pulmonx's return on equity of -48.09% beat NeuroPace's return on equity.
NeuroPace has lower revenue, but higher earnings than Pulmonx. NeuroPace is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroPace beats Pulmonx on 10 of the 18 factors compared between the two stocks.
Get Pulmonx News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
